Capital International Investors
XENE icon

Capital International Investors’s Xenon Pharmaceuticals XENE Stock Holding History

Capital International Investors’s Portfolio XENE Stock Details XENE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$143M Sell
2,361,639
-313,088
-12% -$17.4M 0.03% 261
2026
Q1 		$156M Sell
2,674,727
-740,232
-22% -$34.1M 0.04% 240
2025
Q4 		$153M Buy
3,414,959
+233,466
+7% +$9.81M 0.02% 259
2025
Q3 		$128M Sell
3,181,493
-56
-0% -$1.97K 0.02% 274
2025
Q2 		$99.6M Buy
3,181,549
+92,819
+3% +$3.03M 0.02% 284
2025
Q1 		$104M Buy
3,088,730
+541,520
+21% +$20.6M 0.02% 278
2024
Q4 		$99.9M Sell
2,547,210
-33,962
-1% -$1.4M 0.02% 286
2024
Q3 		$102M Buy
2,581,172
+105,313
+4% +$4.25M 0.02% 274
2024
Q2 		$96.5M Hold
2,475,859
– – 0.02% 271
2024
Q1 		$107M Buy
2,475,859
+20,176
+0.8% +$928K 0.02% 273
2023
Q4 		$113M Buy
2,455,683
+8,863
+0.4% +$313K 0.03% 270
2023
Q3 		$83.6M Buy
2,446,820
+124,829
+5% +$4.67M 0.02% 285
2023
Q2 		$89.4M Hold
2,321,991
– – 0.02% 296
2023
Q1 		$83.1M Buy
2,321,991
+222,412
+11% +$8.22M 0.02% 306
2022
Q4 		$82.8M Buy
2,099,579
+457,071
+28% +$16.6M 0.02% 299
2022
Q3 		$59.3M Buy
1,642,508
+60,000
+4% +$2.16M 0.02% 327
2022
Q2 		$48.1M Buy
1,582,508
+714,211
+82% +$21.6M 0.01% 348
2022
Q1 		$26.5M Sell
868,297
-187,429
-18% -$5.61M 0.01% 390
2021
Q4 		$33M Hold
1,055,726
– – 0.01% 383
2021
Q3 		$16.1M Hold
1,055,726
– – ﹤0.01% 412
2021
Q2 		$19.7M Hold
1,055,726
– – ﹤0.01% 407
2021
Q1 		$18.9M Hold
1,055,726
– – ﹤0.01% 392
2020
Q4 		$16.2M Hold
1,055,726
– – ﹤0.01% 396
2020
Q3 		$11.7M Hold
1,055,726
– – ﹤0.01% 391
2020
Q2 		$13.2M Hold
1,055,726
– – ﹤0.01% 368
2020
Q1 		$12M Hold
1,055,726
– – ﹤0.01% 346
2019
Q4 		$13.8M Hold
1,055,726
– – ﹤0.01% 340
2019
Q3 		$9.51M Hold
1,055,726
– – ﹤0.01% 360
2019
Q2 		$10.4M Hold
1,055,726
– – ﹤0.01% 361
2019
Q1 		$10.7M Buy
1,055,726
+118,326
+13% +$1M ﹤0.01% 352
2018
Q4 		$5.92M Hold
937,400
– – ﹤0.01% 357
2018
Q3 		$12.4M Buy
+937,400
New +$10.9M 0.01% 343

Other funds holding XENE

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Capital International Investors's XENE Position: Q2 2026 in Review

Capital International Investors reduced its Xenon Pharmaceuticals (XENE) stake by 12% in Q2 2026, selling an estimated $17.4M and leaving 2,361,639 shares worth $143M. The position accounts for 0.03% of the portfolio, ranked #261.

Capital International Investors first reported a position in XENE in Q3 2018 and has held it in 32 quarters since. The position peaked at $156M in Q1 2026. 315 funds tracked by Wall St. Rank hold XENE as of Q2 2026.

  • Capital International Investors held 2,361,639 shares of Xenon Pharmaceuticals worth $143M as of Q2 2026.
  • Capital International Investors sold 313,088 Xenon Pharmaceuticals shares in Q2 2026, an estimated $17.4M.
  • Xenon Pharmaceuticals made up 0.03% of Capital International Investors's portfolio in Q2 2026, its #261 holding.
  • Capital International Investors first reported a position in Xenon Pharmaceuticals in Q3 2018 and has held it in 32 quarters since.
  • Capital International Investors's Xenon Pharmaceuticals position peaked at $156M in Q1 2026.
  • 315 funds tracked by Wall St. Rank held Xenon Pharmaceuticals as of Q2 2026.

Based on Capital International Investors's 13F filing for Q2 2026, filed 12 Aug 2026.